| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Attention should be paid to the MHC class I status of neoplasms during the design of immunotherapy protocols. For therapy of MHC class I deficient tumours, cytokines such as IFN gamma, IL-12, IL-2, GM-CSF, either exogenous or produced by gene-modified vaccines, should be considered. The therapeutic role of the induction of MHC class I expression by demethylation and acetylation agents should also be investigated.
- Attention should be paid to the MHC class I status of neoplasms during the design of immunotherapy protocols. For therapy of MHC class I deficient tumours, cytokines such as IFN gamma, IL-12, IL-2, GM-CSF, either exogenous or produced by gene-modified vaccines, should be considered. The therapeutic role of the induction of MHC class I expression by demethylation and acetylation agents should also be investigated. (en)
|
| Title
| - MHC class I status of tumours and design of immunotherapeutic strategies.
- MHC class I status of tumours and design of immunotherapeutic strategies. (en)
|
| skos:prefLabel
| - MHC class I status of tumours and design of immunotherapeutic strategies.
- MHC class I status of tumours and design of immunotherapeutic strategies. (en)
|
| skos:notation
| - RIV/68378050:_____/03:23033192!RIV/2004/GA0/A23004/N
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(GA301/01/0985), P(IAA5052203), P(NC6957), P(NC7148), P(NC7552), Z(AV0Z5052915)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/03:23033192
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - MHC; beta2-mikroglobulin; immunotherapeutic strategies (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...ocetUcastnikuAkce
| |
| http://linked.open...nichUcastnikuAkce
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)